The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1070-1076

  Tan, Daryl ^a,b   Kim, Kihyun ^c   Kim, Jin Seok ^d   Eom, Hyeon Seok ^e   Teoh, Gerrard ^f   Ong, Kiat Hoe ^g   Goh, Yeow Tee ^a   Durie, Brian G M ^h   Chng, Wee Joo ⁱ   Lee, Jae Hoon ^j  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b RAFFLES HOSPITAL   (Singapore)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e National Cancer Center   (South Korea)

^f Tan Tock Seng Hospital ^*

^g TAN TOCK SENG HOSPITAL   (Singapore)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^j Gachon University College of Medicine   (South Korea)

more..

Author keywords

Bortezomib; ISS; Myeloma

Indexed keywords

BORTEZOMIB;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGAPORE; SOUTH KOREA; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME;

BORTEZOMIB; ISS; MYELOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRAZINES; REMISSION INDUCTION; REPUBLIC OF KOREA; SINGAPORE; SURVIVAL RATE; TERTIARY CARE CENTERS; THALIDOMIDE;

EID: 84880936780     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.06.008     Document Type: Article

References (42)

1. Jagannath S., Richardson P.G., Sonneveld P., et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007, 21:151-157.
2. Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisolone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006, 108:2168-2172.
3. Barlogie B., Anaissie E., van Rhee F., et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007, 138:176-185.
4. Jagannath S., Barlogie B., Berenson J.R., et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005, 103(6):1195-1200.
5. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376(9758):2075-2085.
6. Harousseau J.L., Attal M., Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010, 28(30):4621-4629.
7. Kumar S.K., Mikhael J.R., Buadi F.K., et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009, 84(12):1095-1110.
8. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
9. Mateos M.V., Richardson P.G., Schlag R., et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010, 28(13):2259-2266.
10. Fonseca R., Bergsagel P.L., Drach J., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23(12):2210-2221.
11. Arzoumanian V., Hoering A., Sawyer J., et al. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia 2008, 22:850-855.
12. Rajkumar Fonseca R., Dewald G.W., Therneau T.M., et al. Cytogenetic abnormalities correlate with the plasma cell labelling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999, 113(1):73-77.
13. Boccadoro M., Massaia M., Dianzani U., et al. Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index. Haematologica 1987, 72(2):171-175.
14. Rajkumar S.V., Greipp P.R. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999, 13:1295-1314.
15. Tan D., Teoh G., Lau L.C., et al. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. Am J Hematol 2010, 85:752-756.
16. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc 1958, 53:457-484.
17. Peto R., Pike M.C. Conservatism of the approximation sigma (O-E)2-E in the log rank test for survival data or tumor incidence data. Biometrics 1973, 29:579-584.
18. Cox D.R. Regression models and life-tables. J Roy Statistical Society B 1972, 34:187-220.
19. Durie B.G., Harousseau J.L., San Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
20. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111(5):2516-2520.
21. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
22. Kristinsson S.Y., Landgren O., Dickman P.W., et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007, 25:1993-1999.
23. Kastritis E., Zervas K., Symeonidis A., et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009, 23(6):1152-1157.
24. Rajkumar S.V., Gahrton G., Bergsagel P.L. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011, 118:3205-3211.
25. Rajkumar S.V. Treatment of myeloma: cure vs control. Mayo Clinic Proc 2008, 83:1142-1145.
26. Fonseca R. Many and multiple myeloma(s). Leukemia 2003, 17(10):1943-1944.
27. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64(4):1546-1558.
28. Stewart A.K., Bergsagel P.L., Greipp P.R., et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007, 21(3):529-534.
29. Rajkumar S.V. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012, 87:79-88.
30. Jagannath S., Barlogie B., Berenson J.R., et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005, 103:1195-1200.
31. Dimopoulos M.A., Terpos E., Chanan-Khan A., et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010, 28(33):4976-4984.
32. Jacobson J., Hussein M., Barlogie B., et al. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003, 122:441-450.
33. Durie B.G.M., Kyle R., Belch A., et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003, 4:379-398.
34. Bologa R.M., Levine D.M., Parker T.S., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998, 32:107-114.
35. Harousseau J.L., Avet-Loiseau H., Attal M., et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol 2009, 27:5720-5726.
36. Lahuerta J., Mateos M., Martínez-López J., et al. Influence of pre- and posttransplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008, 26:5775-5782.
37. Dingli D., Pacheco J.M., Nowakowski G.S., et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007, 25:4933-4937.
38. Martinez-Lopez J., Blade J., Mateos M.V., et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011, 118(3):529-534.
39. Morgan G.J., Gregory W.M., Davies F.E., et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012, 119(1):7-15.
40. Zamagni E., Testoni N., Terragna C., et al. Prognostic impact of cytogenetic abnormalities on outcomes of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous stem-cell transplantation: an analysis of 593 patients. Blood 2010, 116. abstract 3562.
41. Kapoor P., Kumar S., Mandrekar S.J., et al. Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. Leukemia 2011, 25:1195-1197.
42. Rajkumar S.V., Blood E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24:431-436.